<DOC>
	<DOCNO>NCT02534467</DOCNO>
	<brief_summary>An open-label ( outcome assessor blind ) prospective crossover cohort study child 6-16 year assess effect Montelukast moderate severe atopic dermatitis .</brief_summary>
	<brief_title>Does Treatment With Montelukast Improve Symptoms Atopic Dermatitis Children ?</brief_title>
	<detailed_description>An open-label , prospective cohort study two arm 16 week comprise 8 week treatment montelukast 8 week without treatment montelukast . All patient follow recruitment study end date . Study Population 62 patient age 6-16 year old moderate severe atopic dermatitis recruit Royal Children 's Hospital Box Hill Hospital dermatology clinic already previously receive eczema education ( SCORAD &gt; 25 ) Study Product Oral tablet montelukast Dose Regimen For patient 6-8 year old - 4mg montelukast daily For patient 9-13 year old - 5mg montelukast daily For patient 14-16 year old - 10mg montelukast daily Evaluation Criteria Primary objective measurement : mean change SCORAD index 8 week Patients randomize 2 arm : Arm 1 treat montelukast therapy 8 week follow montelukast therapy 8 week . Arm 2 follow 8 week without montelukast therapy follow 8 week montelukast therapy . Assessment Schedule Clinical assessment conduct baseline ( week 0 ) , review every 4 week 16 week safety follow-up visit 2 week treatment end ( week 18 ) . At first clinic visit , demographic data , medical history baseline SCORAD cDLQI record . cDLQI complete participant . Participants SCORAD &lt; 25 consider mild disease include study . Suitable participant prescribe oral montelukast adjunct standard topical therapy ( corticosteroid , emollient ) immunosuppressive therapy . Adverse effect , SCORAD ( assess blind assessor ) cDLQI assess review . Data analyze base intention-to-treat . Paired data SCORAD cDLQI analyze . A p value &lt; 0.05 consider statistically significant . A 30 % improvement SCORAD cDLQI score consider clinically significant .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Patients age 616 year old moderate severe atopic dermatitis ( SCORAD &gt; 25 ) despite topical therapy ( corticosteroids emollient ) least 2 month Patients age 616 year old moderate severe atopic dermatitis ( SCORAD &gt; 25 ) despite immunosuppressive therapy ( azathioprine , cyclosporine , methotrexate ) least 2 month Patients mild atopic dermatitis ( SCORAD &lt; 25 ) Patients receive phototherapy past 8 week Patients history sensitivity leukotriene receptor antagonist</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>